Loading company…
Suzhou-based biotechnology company focused on drug research and development in oncology and autoimmune inflammatory diseases.
Xinkanghe, established in 2015 and based in Suzhou, China, develops new drug targets and drug combinations for oncology and autoimmune inflammatory diseases, with a focus on immunotherapeutic antibodies. Its first antibody drug received clinical trial approvals in February 2020. The company raised CNY 115 million in Series A funding in November 2018, led by Northern Light Venture Capital, and over CNY 100 million in Series B+ funding in July 2023, led by GTJA Investment Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in